Pancreatic Cancer Differential Methylation Atlas in Blood, Peri-carcinomatous and Diseased Tissue

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117387

Authors

Huan Wang

Fan Yin

Fang Yuan

Yuehua Men

Muhong Deng

Yang Liu

Qingfang Li

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer is common in elderly persons, and less than 20% of patients present with localized, potentially curable tumors.

Methods: We compared the methylated sites and genes in pericarcinous tissues compared to cancer tissue, and blood compared to pericarcinous tissues in order to harvest methylation markers for putative diagnostic and therapy monitoring purposes.

Results: Of 15,397 CpG sites detected in 7,440 genes, 5,605 (36.4%, 5,605 of 15,397) CpG sites were hypomethylated and 5,870 (38.12%, 5,870 of 15,397) CpG sites were hypermethylated. We then performed Gene Ontology (GO) and KEGG analysis to systematically characterize the ten significantly differentially methylated genes: , , , , , , , , , and . Meanwhile, function analysis of genes with differentially methylated sites located in promoter regions of overlap group was also performed. According to previous studies, we further screened 22 pancreatic cancer related key genes. The results suggested that these key genes can influence methylation. GO and KEGG analysis indicated that these genes are involved in a wide range of functions.

Conclusions: The identification of differentially methylated genes in this study provides valuable information for liquid biopsy methylation markers in pancreatic cancer.

Citing Articles

Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer.

Bararia A, Chakraborty P, Roy P, Chattopadhay B, Das A, Chatterjee A World J Gastroenterol. 2023; 29(15):2241-2260.

PMID: 37124888 PMC: 10134423. DOI: 10.3748/wjg.v29.i15.2241.

References

Petronis A, Gottesman I, Crow T, DeLisi L, Klar A, Macciardi F . Psychiatric epigenetics: a new focus for the new century. Mol Psychiatry. 2000; 5(4):342-6. DOI: 10.1038/sj.mp.4000750. View

Wang L, Ni Y, Su B, Mu X, Shen H, Du J . MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol. 2013; 42(3):957-62. DOI: 10.3892/ijo.2013.1767. View

Ehrlich M . DNA methylation in cancer: too much, but also too little. Oncogene. 2002; 21(35):5400-13. DOI: 10.1038/sj.onc.1205651. View

Deaton A, Webb S, Kerr A, Illingworth R, Guy J, Andrews R . Cell type-specific DNA methylation at intragenic CpG islands in the immune system. Genome Res. 2011; 21(7):1074-86. PMC: 3129250. DOI: 10.1101/gr.118703.110. View

Sun Z, Chai H, Wu Y, White W, Donkena K, Klein C . Batch effect correction for genome-wide methylation data with Illumina Infinium platform. BMC Med Genomics. 2011; 4:84. PMC: 3265417. DOI: 10.1186/1755-8794-4-84. View

Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F . Evaluation of the Infinium Methylation 450K technology. Epigenomics. 2011; 3(6):771-84. DOI: 10.2217/epi.11.105. View

Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y . Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 2011; 7(3):e1001356. PMC: 3069107. DOI: 10.1371/journal.pgen.1001356. View

Illingworth R, Gruenewald-Schneider U, Webb S, Kerr A, James K, Turner D . Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet. 2010; 6(9):e1001134. PMC: 2944787. DOI: 10.1371/journal.pgen.1001134. View

Ebert M, HERNBERG S, Fei G, Sokolowski A, Schulz H, Lippert H . Induction and expression of cyclin D3 in human pancreatic cancer. J Cancer Res Clin Oncol. 2001; 127(7):449-54. DOI: 10.1007/s004320100235. View

10.

Hassan M, Bondy M, Wolff R, Abbruzzese J, Vauthey J, Pisters P . Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007; 102(12):2696-707. PMC: 2423805. DOI: 10.1111/j.1572-0241.2007.01510.x. View

11.

Bhutani N, Burns D, Blau H . DNA demethylation dynamics. Cell. 2011; 146(6):866-72. PMC: 3236603. DOI: 10.1016/j.cell.2011.08.042. View

12.

Jin S, Mu Y, Wang X, Liu Z, Wan L, Xiong Y . Overexpressed RACK1 is positively correlated with malignant degree of human colorectal carcinoma. Mol Biol Rep. 2014; 41(5):3393-9. DOI: 10.1007/s11033-014-3201-y. View

13.

Irizarry R, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P . The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009; 41(2):178-186. PMC: 2729128. DOI: 10.1038/ng.298. View

14.

Yi J, Guzzetta A, Bailey V, Downing S, Van Neste L, Chiappinelli K . Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013; 19(23):6544-6555. PMC: 4310572. DOI: 10.1158/1078-0432.CCR-12-3224. View

15.

Landi S . Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res. 2009; 681(2-3):299-307. DOI: 10.1016/j.mrrev.2008.12.001. View

16.

Nones K, Waddell N, Song S, Patch A, Miller D, Johns A . Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 2014; 135(5):1110-8. DOI: 10.1002/ijc.28765. View

17.

Jiao L, Zhu J, Hassan M, Evans D, Abbruzzese J, Li D . K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas. 2007; 34(1):55-62. PMC: 1905887. DOI: 10.1097/01.mpa.0000246665.68869.d4. View

18.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

19.

Gansauge S, Gansauge F, Ramadani M, STOBBE H, Rau B, Harada N . Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997; 57(9):1634-7. View

20.

Mao X, Cai T, Olyarchuk J, Wei L . Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics. 2005; 21(19):3787-93. DOI: 10.1093/bioinformatics/bti430. View